...
首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
【24h】

EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.

机译:EGFR-突变体肺腺癌与新型EGFR抑制剂XL647的XL647进行了一线,随后可以保留对厄洛替尼的中等敏感性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: EGFR-mutant lung cancers are sensitive to EGFR tyrosine kinase inhibitors (TKIs). Unfortunately, they develop resistance, often due to acquisition of a second-site mutation (T790M). Current EGFR TKIs select for T790M in preclinical models of acquired resistance. We explored whether all EGFR TKIs similarly select for the T790M mutation using data from early clinical trials and established in vitro models of acquired resistance. METHODS: We analyzed the clinical characteristics of eight patients with metastatic EGFR-mutant lung adenocarcinoma who were treated first-line with XL647 and then progressed. XL647 is an ATP-competitive inhibitor of EGFR, HER2, KDR, and EPHB4. Additional molecular preclinical studies were performed to characterize resistance. RESULTS: Four patients displayed confirmed partial responses (PRs), three patients had unconfirmed PRs, and one patient displayed stable disease. Only one of five patients' tumor samples available for analysis after disease progression harbored the T790M mutation. Eight patients subsequently received erlotinib, with (n = 3) or without (n = 5) chemotherapy. Three of five patients treated with single-agent erlotinib derived additional benefit, staying on drug up to 9 months. EGFR-mutant PC-9 cells with acquired resistance to XL647 did not harbor the T790M mutation, displayed a distinct mRNA profile from PC-9 cells with T790M-mediated resistance, and were moderately sensitive to erlotinib in growth inhibition assays. Crystal structure analyses of XL647/EGFR T790M did not reveal a different binding mode from that of erlotinib. CONCLUSIONS: The findings of this exploratory study suggest that different EGFR TKIs may select for distinct mechanisms of resistance. These results raise the possibility that different EGFR TKIs could be sequentially used to improve outcomes in patients with EGFR-mutant lung cancer. Further work investigating this hypothesis is warranted.
机译:简介:EGFR-突变体肺癌对EGFR酪氨酸激酶抑制剂(TKI)敏感。不幸的是,它们造成抵抗力,通常是由于采集第二位点突变(T790M)。目前EGFR TKI在获得电阻的临床前模型中选择T790M。我们探讨了所有EGFR TKIS是否类似地使用早期临床试验的数据选择T790M突变,并建立了获得性能的体外模型。方法:对XL647的一线进行治疗,分析了八个转移性EGFR-突变体肺腺癌患者的临床特征。 XL647是EGFR,HER2,KDR和EPHB4的ATP竞争抑制剂。进行额外的分子临床前研究表征抗性。结果:4名患者显示确诊的部分反应(PRS),三名患者未经证实的PRS,一名患者显示出稳定的疾病。在疾病进展后,只有五名患者肿瘤样品中的肿瘤样品中只有一个患有T790M突变。 8名患者随后接受厄洛替尼,(n = 3)或没有(n = 5)化疗。三种患者中的三种患者,用单体剂ERLOTINIB衍生出额外的益处,持续超过9个月的药物。具有获取耐受XL647的抗蛋白酶PC-9细胞未含有T790M突变,从PC-9细胞显示出具有T790M介导的抗性的不同的mRNA谱,并对厄洛替尼在生长抑制测定中适度敏感。 XL647 / EGFR T790M的晶体结构分析没有揭示厄洛替尼的不同绑定模式。结论:该探索性研究的结果表明,不同的EGFR TKI可以选择不同的抵抗机制。这些结果提高了不同EGFR TKIS可以依次用于改善EGFR-突变体肺癌患者的结果的可能性。认证调查这一假设的进一步工作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号